Marisa Wexler, MS,  senior science writer—

A newly launched company known as HD Immune, based in Vienna, is working to develop an antibody treatment for Huntington’s disease. The potential therapy showed promise in a mouse model, according to the study, “Reducing huntingtin by immunotherapy delays disease progression in a mouse…

The Huntington’s Disease Society of America (HDSA) has awarded $898,194 in funding to support six research projects aiming to better understand and find more effective treatments for Huntington’s disease (HD). Grants were awarded through the HD Human Biology Project, HDSA’s largest research initiative supporting work focused…

Harness Therapeutics has secured an additional £4 million (about $5 million) in funding, which the U.K. biotech company plans to use to advance development of an experimental treatment for Huntington’s disease. “This further investment puts us in a strong position to address multiple neurodegenerative disease pathways, with an…

Nearly a year of treatment with Neurocrine Biosciences’ Ingrezza (valbenazine) leads to sustained reductions in uncontrolled movements known as chorea in adults with Huntington’s disease, according to interim data from a Phase 3 trial called KINECT-HD2. “The 50-week data from the ongoing KINECT-HD2 study provide insight on the…

A four-week titration kit for starting on Austedo (deutetrabenazine) — an approved therapy for chorea, or involuntary muscle contractions, due to Huntington’s disease — has so far been well-received by patients in a Phase 4 clinical trial. Titration, in medicine, means starting a drug at a low dose…

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to SAGE-718, Sage Therapeutics’ experimental oral therapy for Huntington’s disease. The FDA gives this designation to therapies that have the potential to treat rare diseases, which are defined as conditions that affect fewer than 200,000 people…

The recent approval in the U.S. of Ingrezza (valbenazine) for adults with Huntington’s disease-associated chorea means patients now have access to a treatment option that’s likely easier to take, according to the chief medical officer of Neurocrine Biosciences, the therapy’s maker. “Ingrezza is always one capsule,…

Alternative splicing, a molecular process that’s crucial for genes being “read” to produce proteins, is dysregulated in Huntington’s disease from the early stages of neuronal development, a study indicates. Notably, splicing changes were found to be dependent on the length of CAG repeats in the HTT gene — the cause…

Folia Health is expanding the use of its patient-centered Folia app, designed to collect and manage patient-reported health data, to people with Huntington’s disease (HD). The free app lets patients with certain conditions — now including known or suspected Huntington’s — to record and visualize information about their…

The genetic mutation behind Huntington’s disease may cause neurodegeneration through the production a toxic form of the huntingtin protein, but abnormally long RNA molecules that form gel-like structures that gum up protein production might play a role too. These are the findings of a new study that’s part of…